TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells. [electronic resource]
Producer: 20171009Description: e2290 p. digitalISSN:- 2041-4889
- Animals
- Anthraquinones -- pharmacology
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- pathology
- Cell Line, Tumor
- Cell Survival -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- ErbB Receptors -- antagonists & inhibitors
- Gefitinib
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Lung Neoplasms -- pathology
- Mice, Inbred BALB C
- Mice, Nude
- Mutation -- genetics
- Proteasome Endopeptidase Complex -- metabolism
- Protein Kinase Inhibitors -- pharmacology
- Proteolysis -- drug effects
- Proto-Oncogene Proteins c-met -- antagonists & inhibitors
- Quinazolines -- pharmacology
- Tumor Stem Cell Assay
- Ubiquitin -- metabolism
- Ubiquitination -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.